Abstract
Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have